Adler Y, Finkelstein Y, Guindo J, Rodriguez de la Serna A, Shoenfeld Y, Bayes-Genis A, Sagie A, Bayes de Luna A, Spodick D H
Department of Cardiology, Rabin Medical Center, Petah Tiqva, Israel.
Circulation. 1998 Jun 2;97(21):2183-5. doi: 10.1161/01.cir.97.21.2183.
The most troublesome complication of acute pericarditis is recurrent episodes of pericardial inflammation, occurring in 15% to 32% of cases. The cause of the recurrence is usually unknown, although in some cases it may be traced to viral infection or may be a consequence of coronary artery bypass grafting. The optimal method for prevention has not been fully established; accepted modalities include nonsteroidal anti-inflammatory drugs, corticosteroids, immunosuppressive agents, and pericardiectomy.
Based on the proven efficacy of colchicine therapy for familial Mediterranean fever (recurrent polyserositis), several small studies have used colchicine successfully to prevent recurrence of acute pericarditis after failure of conventional treatment. Recently, we reported the results from the largest multicenter international study on 51 patients who were treated with colchicine to prevent further relapses and who were followed up for < or = 10 years.
In light of new trial data that have accumulated in the past decade, we review the evidence for the efficacy and safety of colchicine for the prevention of recurrent episodes of pericarditis. Clinical and personal experience shows that colchicine may be an extremely promising adjunct to conventional treatment and may ultimately serve as the initial mode of treatment, especially in idiopathic cases.
急性心包炎最棘手的并发症是心包炎症反复发作,发生率为15%至32%。复发原因通常不明,不过在某些情况下可能可追溯至病毒感染或冠状动脉搭桥手术的后果。预防的最佳方法尚未完全确立;公认的方式包括非甾体抗炎药、皮质类固醇、免疫抑制剂和心包切除术。
基于秋水仙碱治疗家族性地中海热(复发性多浆膜炎)已证实的疗效,多项小型研究成功使用秋水仙碱预防了传统治疗失败后的急性心包炎复发。最近,我们报告了一项最大规模的多中心国际研究结果,该研究对51例接受秋水仙碱治疗以预防进一步复发且随访时间≤10年的患者进行了研究。
鉴于过去十年积累的新试验数据,我们回顾了秋水仙碱预防心包炎复发的疗效和安全性证据。临床和个人经验表明,秋水仙碱可能是传统治疗极有前景的辅助药物,最终可能成为初始治疗方式,尤其是在特发性病例中。